Context Therapeutics Inc.
CNTX
$1.09
$0.032.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.67M | 7.66M | 7.44M | 7.22M | 7.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.21M | 38.30M | 31.63M | 29.92M | 32.55M |
| Operating Income | -30.21M | -38.30M | -31.63M | -29.92M | -32.55M |
| Income Before Tax | -26.44M | -34.21M | -27.63M | -26.73M | -30.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.44 | -34.21 | -27.63 | -26.73 | -30.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.44M | -34.21M | -27.63M | -26.73M | -30.15M |
| EBIT | -30.21M | -38.30M | -31.63M | -29.92M | -32.55M |
| EBITDA | -30.19M | -38.29M | -31.62M | -29.91M | -32.54M |
| EPS Basic | -0.28 | -0.40 | -0.35 | -0.53 | -0.91 |
| Normalized Basic EPS | -0.18 | -0.25 | -0.22 | -0.33 | -0.57 |
| EPS Diluted | -0.33 | -0.44 | -0.39 | -0.57 | -0.91 |
| Normalized Diluted EPS | -0.18 | -0.25 | -0.22 | -0.33 | -0.57 |
| Average Basic Shares Outstanding | 367.49M | 352.79M | 312.56M | 233.34M | 167.37M |
| Average Diluted Shares Outstanding | 367.49M | 352.79M | 312.56M | 233.34M | 167.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |